{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Guieze R"],"pubmed_abstract":["Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 μg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle o"],"journal":["Nature communications"],"pagination":["6822"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11316063"],"repository":["biostudies-literature"],"pubmed_title":["Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial."],"pmcid":["PMC11316063"],"pubmed_authors":["Lazarian G","Quittet P","Quinquenel A","Molina L","Clavert A","Michallet AS","Rouille V","Schwartz D","Saad A","Aurran T","Hivert B","Broseus J","Roos-Weil D","Magnin B","Fornecker LM","Tournilhac O","Ysebaert L","Pereira B","Guieze R","Ferrant E","de Guibert S","Drenou B","Laribi K","de Antonio M","Feugier P","Laurent C","Veronese L","Gay J"],"additional_accession":[]},"is_claimable":false,"name":"Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.","description":"Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 μg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle o","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-01T07:23:18.366Z","creation":"2024-12-03T15:09:10.567Z"},"accession":"S-EPMC11316063","cross_references":{"pubmed":["39122717"],"doi":["10.1038/s41467-024-51264-2"]}}